Fusion AntibodiesLSE:FAB 33 FCF Margin % is -74.82% as of Sep. 2025. GuruFocus rates LSE:FAB with a GF Score™ of 33/100 and a GF Value™ of £0.04 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 959 Biotechnology companies, Fusion Antibodies ranks better than 50.57% on this metric.
The historical rank and industry rank for Fusion Antibodies's FCF Margin % or its related term are showing as below:
LSE:FAB'
s FCF Margin % Range Over the Past 10 Years
Min: -155.9 Med: -24.86 Max: 21
Current: -77.63
During the past 11 years, the highest FCF Margin % of Fusion Antibodies was 21.00%. The lowest was -155.90%. And the median was -24.86%.
LSE:FAB's FCF Margin % is ranked better than 50.57% of 959
companies
in the Biotechnology industry
Industry Median: -84.65
vs LSE:FAB: -77.63
Fusion Antibodies FCF Margin % Related Terms
Fusion Antibodies FCF Margin % Historical Data
* Premium members only.
The historical data trend for Fusion Antibodies's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LSE:FAB vs VRTX, REGN, ALNY: FCF Margin % Comparison
For the Biotechnology subindustry, Fusion Antibodies's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fusion Antibodies FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Fusion Antibodies's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Fusion Antibodies's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fusion Antibodies (LSE:FAB) has a FCF Margin % of -74.82% as of Sep. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Fusion Antibodies and its competitors. According to the industry distribution chart, Fusion Antibodies ranks #474 out of 959 companies in the Biotechnology industry, placing it in the top 49.4%.
Is Fusion Antibodies' FCF Margin % too high?
Fusion Antibodies' current FCF Margin % is -74.82%. Based on the distribution chart, Fusion Antibodies ranks #474 out of 959 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Fusion Antibodies has a GF Score™ of 33/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Fusion Antibodies' FCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Fusion Antibodies ranks #474 out of 959 companies for FCF Margin %. This puts Fusion Antibodies in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Fusion Antibodies and its competitors. Fusion Antibodies's current FCF Margin % is -74.82%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fusion Antibodies stock overvalued right now?
Based on GuruFocus' analysis, Fusion Antibodies (LSE:FAB) is currently considered Significantly Overvalued. The stock's GF Value™ is £0.04, compared to a current price of £0.12 — trading 187.5% above its estimated fair value. The current FCF Margin % is -74.82%. Fusion Antibodies' overall GF Score™ is 33/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Fusion Antibodies (LSE:FAB), the current FCF Margin % is -74.82% as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fusion Antibodies (LSE:FAB) Overvalued in 2026?
Based on GuruFocus' analysis, Fusion Antibodies stock appears to be overvalued.
The current stock price of £0.12 is trading 187.5% above its estimated GF Value™ of £0.04.
GuruFocus considers Fusion Antibodies to be Significantly Overvalued.
Key valuation signals for LSE:FAB:
FCF Margin %: -74.82%
GF Value™: £0.04 vs. price of £0.12 (187.5% above fair value)
No single metric tells the full story. See the LSE:FAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fusion Antibodies PLC is a Contract Research Organisation (CRO) providing antibody identification, engineering, and expression services for the discovery and development of antibodies for human and veterinary therapeutics, as well as for diagnostics. Its customers are pharmaceutical, biotech, veterinary, diagnostic, and life science research companies. The company's three core service areas include: Discovery (identification, screening, and sequencing of novel antibodies); Engineering (optimising the performance of antibodies); and Supply (production and purification of antibodies for further development). Geographically company generates the majority of its revenue from North America and the Rest of the World, followed by the United Kingdom and the Rest of Europe.
33GF Score
Get the complete analysis for LSE:FAB
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:FAB has been successfully added to your 
